{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:49:32Z","timestamp":1790174972782,"version":"4.1.0"},"reference-count":73,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>RNA-based immunization strategies have emerged as promising alternatives to conventional vaccine approaches. A substantial body of published work demonstrates that RNA vaccines can elicit potent, protective immune responses against various pathogens. Consonant with its huge impact on public health, influenza virus is one of the best studied targets of RNA vaccine research. Currently licensed influenza vaccines show variable levels of protection against seasonal influenza virus strains but are inadequate against drifted and pandemic viruses. In recent years, several types of RNA vaccines demonstrated efficacy against influenza virus infections in preclinical models. Additionally, comparative studies demonstrated the superiority of some RNA vaccines over the currently used inactivated influenza virus vaccines in animal models. Based on these promising preclinical results, clinical trials have been initiated and should provide valuable information about the translatability of the impressive preclinical data to humans. This review briefly describes RNA-based vaccination strategies, summarizes published preclinical and clinical data, highlights the roadblocks that need to be overcome for clinical applications, discusses the landscape of industrial development, and shares the authors\u2019 personal perspectives about the future of RNA-based influenza virus vaccines.<\/jats:p>","DOI":"10.3390\/vaccines6020020","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T12:32:20Z","timestamp":1522672340000},"page":"20","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["New Kids on the Block: RNA-Based Influenza Virus Vaccines"],"prefix":"10.3390","volume":"6","author":[{"given":"Francesco","family":"Scorza","sequence":"first","affiliation":[{"name":"PATH\u2019s Center for Vaccine Innovation and Access, 455 Massachusetts Ave. NW, Suite 1000, Washington, DC 20001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-6242","authenticated-orcid":false,"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"ref_1","unstructured":"(2018, February 20). Up to 650 000 People Die of Respiratory Diseases Linked to Seasonal Flu Each Year. Available online: http:\/\/www.who.int\/mediacentre\/news\/releases\/2017\/seasonal-flu\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Andrews, S.F., Graham, B.S., Mascola, J.R., and McDermott, A.B. (2017). Is It Possible to Develop a \u201cUniversal\u201d Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. Cold Spring Harb. Perspect. Biol.","DOI":"10.1101\/cshperspect.a029413"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From Original Antigenic Sin to the Universal Influenza Virus Vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Krammer, F., Garcia-Sastre, A., and Palese, P. (2017). Is It Possible to Develop a \u201cUniversal\u201d Influenza Virus Vaccine? Toward a Universal Influenza Virus Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development. Cold Spring Harb. Perspect. Biol.","DOI":"10.1101\/cshperspect.a028845"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Altman, M.O., Angeletti, D., and Yewdell, J.W. (2018). Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift. Viral Immunol.","DOI":"10.1089\/vim.2017.0129"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/587643","article-title":"Safety and immunogenicity of trivalent inactivated influenza vaccine in infants","volume":"197","author":"Halasa","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","article-title":"In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies","volume":"30","author":"Hoerr","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","article-title":"Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","article-title":"In vitro transcription of long RNA containing modified nucleosides","volume":"969","author":"Pardi","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","article-title":"Codon bias and heterologous protein expression","volume":"22","author":"Gustafsson","year":"2004","journal-title":"Trends Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","article-title":"HPLC purification of in vitro transcribed long RNA","volume":"969","author":"Weissman","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V66.5.1149.1149","article-title":"Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes","volume":"66","author":"Ross","year":"1985","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.1016\/S0021-9258(19)40646-7","article-title":"Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions","volume":"250","author":"Martin","year":"1975","journal-title":"J. Biol. Chem."},{"key":"ref_22","first-page":"1486","article-title":"Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(3\u2032-O-methyl)GpppG and 7-methyl (3\u2032-deoxy)GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2015.986104","article-title":"Lipid-based mRNA vaccine delivery systems","volume":"14","author":"Midoux","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/j.vaccine.2015.06.112","article-title":"Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone","volume":"33","author":"Medina","year":"2015","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wu, N.C., Zost, S.J., Thompson, A.J., Oyen, D., Nycholat, C.M., McBride, R., Paulson, J.C., Hensley, S.E., and Wilson, I.A. (2017). A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006682"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J.B., De Gregorio, E., Geall, A.J., Brazzoli, M., and Bertholet, S. (2016). Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161193"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin","volume":"90","author":"Brazzoli","year":"2015","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1128\/JVI.77.19.10394-10403.2003","article-title":"An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector","volume":"77","author":"Perri","year":"2003","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.adgen.2014.10.005","article-title":"Self-amplifying mRNA vaccines","volume":"89","author":"Brito","year":"2015","journal-title":"Adv. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1038\/emi.2013.54","article-title":"Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice","volume":"2","author":"Hekele","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/mtna.2014.24","article-title":"Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo","volume":"3","author":"McCullough","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.nano.2015.11.001","article-title":"Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines","volume":"12","author":"Milona","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4161\/hv.25181","article-title":"A novel, disruptive vaccination technology: Self-adjuvanted RNActive\u00ae vaccines","volume":"9","author":"Kallen","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Schnee, M., Vogel, A.B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., and Stitz, L. (2016). An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004746"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"NPJ Vaccines"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4049\/jimmunol.1701005","article-title":"Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination","volume":"200","author":"Lin","year":"2018","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3389\/fimmu.2017.01539","article-title":"Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells","volume":"8","author":"Lindgren","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1016\/j.vaccine.2017.03.094","article-title":"Advancing new vaccines against pandemic influenza in low-resource countries","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/592172","article-title":"Safety and immunogenicity of an inactivated influenza A\/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: Results of a phase I-II randomized clinical trial","volume":"198","author":"Keitel","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-017-0017-5","article-title":"H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines","volume":"2","author":"Wong","year":"2017","journal-title":"NPJ Vaccines"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_56","unstructured":"Mass General News (2018, February 20). Mass. Available online: http:\/\/www.massgeneral.org\/News\/pressrelease.aspx?id=1816."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.immuni.2017.09.007","article-title":"The Pathway to a Universal Influenza Vaccine","volume":"47","author":"Paules","year":"2017","journal-title":"Immunity"},{"key":"ref_58","unstructured":"(2018, February 20). World Health Organization (WHO). Available online: http:\/\/www.who.int\/immunization\/documents\/ISBN_978-92-4-151246-6\/en\/."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/cid\/ciu924","article-title":"Validation of the wild-type influenza A human challenge model H1N1pdMIST: An A(H1N1)pdm09 dose-finding investigational new drug study","volume":"60","author":"Memoli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12985-015-0240-5","article-title":"Characterisation of a wild-type influenza (A\/H1N1) virus strain as an experimental challenge agent in humans","volume":"12","author":"Watson","year":"2015","journal-title":"Virol. J."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Fullen, D.J., Noulin, N., Catchpole, A., Fathi, H., Murray, E.J., Mann, A., Eze, K., Balaratnam, G., Borley, D.W., and Gilbert, A. (2016). Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157211"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"Talaat","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_63","unstructured":"U.S (2018, February 20). Food and Drug Administration (FDA), Available online: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm294307.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine: Translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: Implications for vaccine design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.0608647104","article-title":"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation","volume":"104","author":"Kannemeier","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood-2006-08-040691","article-title":"Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor","volume":"110","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4161\/hv.27600","article-title":"Bringing influenza vaccines into the 21st century","volume":"10","author":"Settembre","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1021\/pr400329k","article-title":"Comparative Glycomics Analysis of Influenza Hemagglutinin (H5N1) Produced in Vaccine Relevant Cell Platforms","volume":"12","author":"An","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_70","unstructured":"(2018, February 20). Assessing the Programmatic Suitability of Vaccine Candidates for WHO Prequalification. Available online: http:\/\/apps.who.int\/iris\/handle\/10665\/76537."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"24402","DOI":"10.1038\/srep24402","article-title":"Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies","volume":"6","author":"Schotsaert","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coviro.2016.02.002","article-title":"Novel universal influenza virus vaccine approaches","volume":"17","author":"Krammer","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection","volume":"212","author":"Monto","year":"2015","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/2\/20\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:59:19Z","timestamp":1760194759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/2\/20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["vaccines6020020"],"URL":"https:\/\/doi.org\/10.3390\/vaccines6020020","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}